About PCEC
Mission
Our mission is to save lives through awareness and the education of men, the women in their lives as well as the medical community about the prevalence of prostate cancer, the importance of early detection, available treatment options and other men’s health issues. To conduct nation wide screenings for men and perform research that will help the detection and treatment of prostate cancer and other mens health issues.
History
The Prostate Conditions Education Council (PCEC) was founded in 1989, and is a non-profit 501-3c organization. The Council is comprised of a consortium of leading physicians, health educators, scientists and prostate cancer advocates.
As the founder and coordinator of the national Prostate Cancer Awareness Week (PCAW) Program, we have screened nearly 5,000,000 men across the country for the disease and have become one of the largest and most successful health screening projects in the world. Through hundreds of hospitals, clinics, private physicians and health centers we are able to bring free screenings each year to more than 125,000 men.
In addition to screenings, PCEC has extraordinarily successful education and awareness campaigns. By incorporating a wide variety of forums we are able to reach millions of people every year with our life-saving messages.
Successes
At the time the PCEC was formed, nearly half of the diagnosed prostate cancer cases had spread beyond the prostate gland, greatly reducing chances for successful treatment. Since PCAW was initiated in 1989, nearly 60% of new prostate cancer cases are discovered when they are still localized and potentially curable, indicating a dramatic increase in awareness among the general public about the importance of early detection.
Number of African American and Hispanic Men Screened
African Americans are twice as likely to get and die from prostate cancer. Recognizing this, PCEC made a huge stride in reaching the African American population and getting them screened. Through a number of our special programs like the Tackle Prostate Cancer program and our Andre Braugher celebrity public service announcement, we were able to increase the number of African American men screened.
Number of PCAW Screening Sites
In addition to screening millions of men during PCAW, the PCEC participates in new research and technology development to help advance the treatment and detection of prostate cancer. Screenings during Prostate Cancer Awareness Week have yielded valuable research results, including data reflecting the positive predictive value of conducting the DRE and the PSA tests together rather than alone. Current research based on our “Know Your Numbers” campaign where we offer cPSA, PSA, total Testosterone and total Cholesterol levels, in addition to collecting body mass index. This research analyzes the relationship between a variety of these variables and several presentations and papers have been published or are waiting to be published in numerous journals such as Adult Urology.
The Prostate Conditions Education Council is a national leader in increasing awareness and education on prostate cancer, current treatments and men’s health issues. Our education and awareness campaigns include a wide variety of forums and have an expansive reach. We have hosted a number of satellite media and radio tours in addition to our national public service announcements. Some of our efforts include the Rudy Giuliani, Straight Talk Campaign, and a public service announcement featuring African-American actor Andre Braugher. Many of the public service announcement campaigns include collateral materials that are distributed nationally at the local level, through our network of screening sites and patients this provides a valuable grass roots connection to a national campaign. Our Tackle Prostate Cancer Program has become one of the top community events with the National Football League (NFL) teams. The Prostate Awareness and Cancer Education (PACE) Race 5K run/walk series is rapidly becoming one of the largest national prostate cancer awareness events.
PACE Race Events
Tackle Prostate Cancer Program Participation
Council Members
E. David Crawford, M.D. - Chairman
Chairman of the PCEC since 1989. Dr. Crawford is professor of surgery, professor of radiation oncology, and head of the Section of Urologic Oncology at the University of Colorado Health Sciences Center (UCHSC) in Denver.
A nationally recognized expert in prostate cancer, Dr. Crawford is the recipient of more than 69 research grants for the study of the following topics: treatment of advanced bladder cancer; metastatic adenocarcinoma of the prostate; hormone-refractory prostate cancer; and several areas of urologic infections and malignancies. He has authored or coauthored over 300 articles published in such journals as Urology, The New England Journal of Medicine, and the Journal of the National Cancer Institute. Dr. Crawford is also an editorial reviewer or consultant for a large number of publications, including Urology, Journal of Urology, The New England Journal of Medicine, Cancer and the Journal of Clinical Oncology.
Dr. Crawford is also an active member of many national and international organizations, including the American Society of Clinical Oncology, the American Urological Association (AUA), and the American Association for the Advancement of Science. Within the AUA, he is a member of the Committee to Study Urologic Research Funding and the Prostate Cancer Clinical Trials Subcommittee. Dr. Crawford also currently serves on the board of the Southwest Oncology Group.
Dr. Crawford’s involvement in the national prostate cancer arena is highly recognized. He has received several honors and awards, including, as co-investigator, the 1999 CaP Cure Annual Award for Scientific Presentation. In 1997, he was presented with a “Freddie Award” at the AMA International Health and Medical Film Competition for the program, ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating), which Dr. Crawford hosted with special guest, retired General Norman Schwarzkopf.
Colonel David G. McLeod, M.D., J.D.
Colonel David G. McLeod, M.D., is Chief of Urologic Oncology at Walter Reed Army Medical Center, Washington, DC and Professor of Surgery at the Uniformed Services University of the Health Sciences, Bethesda, MD. Doctor McLeod is also Director of the Urology Residency Program at Walter Reed Army Medical Center and Clinical Professor in the Department of Surgery (Urology) at Georgetown University Medical Center.
Doctor McLeod is a Colonel in the United States Army Medical Corps. A member of the Medical Department since 1964, Doctor McLeod has received numerous military commendations, including the Legion of Merit award with two Oak Leaf Clusters, Bronze Star, Air Medal, and the Combat Medical Badge for service in Vietnam. Doctor McLeod served as Clearing Platoon Leader and Medical Company Commander of the 1st Brigade 101st Airborne Division while in Vietnam.
An alumnus of the University of North Carolina’s undergraduate and medical schools, Doctor McLeod also holds a J.D. from Northern Virginia Law School. He is a member of numerous professional societies, including the American Society of Clinical Urology, the Society of Urologic Oncology, the American Association of Clinical Urologists, and the Society of Surgical Oncology. In addition, Doctor McLeod is the President of the American Foundation of Urologic Disease whose mission is the prevention and cure of urologic disease, through the expansion of patient education, public awareness, research and advocacy, and Immediate Past President of the Mid-Atlantic Section of the American Urologic Association.
A principal investigator in numerous collaborative studies, Doctor McLeod’s work has appeared in several major medical journals, including Urology, the Journal of Urology, the Journal of Urologic Oncology, and Cancer. He has also co-authored multiple chapters and publications on Urologic Oncology.
Alan Partin, M.D., Ph.D
<!--StartFragment-->
Alan W.Partin M.D., Ph.D., Professor of Urology the Johns Hopkins Medical Institution, has both basic science and clinical interest in prognosis prediction for men with prostate cancer. Dr. Partin's laboratories and clinical and surgical interest are focused on development and testing of new and existing methods for predicting the aggressiveness of prostate cancers so that rational treatment decisions can be made by both patients and physicians. Dr. Partin's laboratories have investigated many new serum tests, some of which are soon to become available for the diagnosis of prostate cancer as well as basics science investigation of new proteins, which may help in detection, and staging of prostate cancer. In addition, Dr. Partin has an academic and clinical interest in treatment of benign prostatic hyperplasia with an emphasis on minimally invasive techniques for treatment of this common disease of men.
Dr. Partin earned his B.A. in chemistry from the University of Mississippi in 1983 and graduating first in his class, he came to Johns Hopkins for his medical training, receiving his Ph.D. degree in 1988 and his M.D. in 1989. He served a surgical internship in 1989, a surgical junior residency in 1990, and his urology residency in 1991, before being named to the faculty as an instructor of urology in 1994. He was promoted to associate professor in 1995 and then to professor of urology in 1999. He is the Bernard L. Schwartz Distinguished Professor of Urologic Oncology.
The author of more than 350 scientific papers, he is also editor in chief of the journal Urology, editor of the leading urology textbook, Campbell-Walsh Textbook of Urology, associate editor of Prostate Cancer and Prostatic Diseases, associate editor of Urology Reviews, and serves on the editorial boards of the Journal of Andrology, Urology Research and Treatment, Current Urology Reports, Clinical Prostate Cancer and the British Journal of Urology.
Neal Shore, M.D., F.A.C.S.
Neal D. Shore, MD, FACS, is the Medical Director of the Carolina Urologic Research Center. Dr. Shore has conducted more than 100 clinical trials, focusing mainly on prostate and bladder disease.
Dr. Shore is a Certified Physician Investigator who has numerous publications in peer-reviewed journals and has lectured extensively on the treatment of prostate cancer and prostate enlargement. He serves on several industry advisory boards as well as academic and advocacy networks: including the Society Urologic Oncology Clinical Trials Consortium, Bladder Cancer Advocacy Network, Large Urology Group Practice Association, and NCI GU Science Steering Committee.
Dr. Shore attended Duke University,’80 and Duke Medical School,’84, Durham, North Carolina. He performed a 6 month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center/Memorial Sloan-Kettering Cancer Center in New York City in 1990. He is the managing partner for Atlantic Urology Clinics, where he has participated in a full-time clinical practice for the past 18 years.
Frank E. Staggers, M.D.
Past President of the California Medical Association is board certified in Urology since 1963 and practices in Oakland, CA. He served as Chief of Urology, Alameda County Medical Center from 1989-2001. Dr. Staggers has been a leader and active member in his many professional organizations as well as well as community based organizations both at the local, state and national levels. He has served as president of the National Medical Association (NMA) and also as president of the California State Chapter. The NMA is the nation’s oldest and largest professional, educational, and scientific organization representing the interests of more than 25,000 African American physicians. He has served at Chair of the Advisory Committee on Minority Physicians for the American Medical Association and as Consultant to the Minority Consortium. Dr. Staggers served as Vice Chair, Chair, and President of the California Medical Association(CMA); an organization of more that 34,000 members. He has held many positions in his local county medical society, including the presidency.Dr. Staggers is a co-founder and Chairs the Ethnic Health Institute(EHI); a community service of Alta Bates Summit Medical Center located in Oakland and Berkeley, California. The Ethnic Health Institute’s mission is to promote the health and well being of the community, with a focus on underserved and minority populations.
Nelson N. Stone, M.D.
Nelson Neal Stone, M.D. is an Attending Physician in the Departments of Urology and Radiation Oncology at Mount Sinai Medical Center in New York City. He is also a Clinical Professor of Urology and Radiation Oncology at Mount Sinai School of Medicine and at the Derald H. Ruttenberg Cancer Center at Mount Sinai. He also serves as Medical Director for ProLogics LLC in Nashville, TN. Dr. Stone earned his medical degree from the University of Maryland in 1979. He completed a general surgical residency in 1981 at the University of Maryland, followed by residencies in urology at the University of Maryland. Dr. Stone then completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center and a research fellowship in biochemical endocrinology at Rockefeller University in 1986.
Dr. Stone has founded several medical companies and serves on the editorial board many scientific journals and is a member of many professional societies, including the Prostate Conditions Education Council, the Society for Minimally Invasive Therapy, the New York State Urological Society, the American Association of Clinical Urologists, and the American Urologic Association.
Dr. Stone has participate in approximately 25 research studies on prostate cancer and has authored over 300 articles, abstracts and book chapters, most on prostate cancer. He invented the real-time technique for prostate seed implantation and is currently training urologists and radiation oncologists in Japan on his method.
Wendy L. Poage, M.H.A.
Wendy Poage earned her Bachelor of Science degree at the Colorado State University in 1993 and her Masters of Health Care Administration at Webster University in 1997. Wendy has been the President of the Prostate Conditions Education Council since 1998. She serves on several committees including Advanced Prostate Cancer Task Force and the Prostate Cancer Advocacy Group. Ms. Poage has vast experience in prostate cancer and urology including leadership positions in a number of renowned educational institutions, hospitals, non-profits and private practices settings. Additionally, she has managed and directed several large NIH and DOD research grants.
Mark A. Moyad, MD, MPH
Dr. Moyad received his masters degree in public health from the University of South Florida where he was one of the lead investigators of the L-tryptophan dietary supplement study that helped to remove this dangerous supplement from the market. He published his first medical article in college on the relationship between a compound found in cottonseed oil and male infertility. He received his M.D. from Wayne State University school of Medicine. He is currently working part-time on his Ph.D. in pathology and N.D. (Naturopathic doctor) degree. He is the author or co-author of 4 books and has 3 additional books coming out in the next 12 months including a guide for Men’s and Women’s Health and a Breast Cancer Prevention Book. He is the primary author of over 60 medical articles. He is the editor of the complementary/ preventive medicine medical book series from Humana press. Dr. Moyad has also been the guest editor of 5 different medical journals. He reviews or edits articles for a number of medical journals including: Urology, Journal of Urology, Cancer, Nutrition and Cancer, British Journal of Urology… He is the director of the Complementary/Preventive medicine course for the Annual American Urologic Association Meeting and the Annual Urologic Nurses Meeting. Dr. Moyad has an endowed chair/directorship at the University of Michigan Medical Center in Complementary and Preventive Medicine. He has had a consulting practice for almost 10 years and he runs clinical trials and basic science studies in regards to complementary/preventive at the University. He has lectured in all 50 states to health professionals and patients and he speaks internationally and gives courses in Europe and Asia on a regular basis. His latest research includes identifying the relationship between lipid changes and cancer risk and treatment. He will also be the co-director of the new Men’s Health program at the University of Michigan in 2004.
Daniel P. Petrylak, MD
Daniel P. Petrylak, MD, is an Associate Professor of Medicine at the Columbia College of Physicians and Surgeons, and director of the Genitourinary Oncology Program at Columbia Presbyterian Center of New York – Presbyterian Hospital.Dr. Petrylak graduated from Columbia College in New York and earned his medical degree from Case Western Reserve University of Medicine in Cleveland , Ohio. He served his internship and residency in internal medicine at Albert Einstein College of Medicine and went on to complete a fellowship in medical oncology at Memorial Sloan Kettering Cancer Center , also both in New York.
A diplomate of internal medicine and medical oncology, Dr. Petrylak has received several grants and funding support from the National Institutes of Health, private foundations such as CaP CURE and the pharmaceutical industry to study cancer treatments. Since 1995, Dr. Petrylak has been a chairman of the Advanced Bladder Subcommittee of the Southwest Oncology Group (SWOG), a network of institutions and investigators working to improve the survival of cancer patients through clinical research.
Dr. Petrylak instructs medical students on the formal principles of cancer chemotherapy as part of the Abnormal Human Biology course at the College of Physicians and Surgeons. He has authored or co-authored numerous articles and abstracts appearing in such peer-reviewed journals as Cancer, Cancer Research, Clinical Cancer Research, Journal of the National Cancer Institute, Nature, Journal of Urology New England Journal of Medicine, and Journal of Clinical Oncology. In addition, Dr. Petrylak has presented his research at numerous medical conferences, had a plenary sessions at ASCO and the AUA this year. He has authored several book chapters, reviews and editorials about the treatment of cancers of the prostate, bladder and kidney.
Dr. Petrylak is a member of several medical societies, including the American Association for Cancer Research, the American Society for Clinical Oncology, and the American Urological Association. He also served as a member of the Devices and Immunologicals Committee of the U.S. Food and Drug Administration (FDA).
